The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its indebted parent.

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned to offload the remainder of shares by striking a deal with its investors to exchange Bausch Health stock for Bausch + Lomb stock.

Bausch + Lomb is working with advisers from Goldman Sachs to test interest from possible buyers, the Financial Times reported on Saturday.

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation from Bausch Health (BHC). Read mroe here.

Shares in Bausch & Lomb surged on Monday amid speculation that the North American contact lens and eye care products supplier is exploring a potential sale.

Key Takeaways Bausch + Lomb is discussing a possible sale that would separate it from its parent company, Bausch Health Cos.Bausch Health is saddled with debt of $21 billion, nearly $10 billion of which is set to mature in 2027.

Bausch & Lomb (NYSE:BLCO) rose 1.8% in premarket trading after a report about private equity interest in a takeover of the eyecare company. Private equity firms including Blackstone (BX), Advent International,